Aehr Test Systems vs. C3.ai: Which Technology Stock Is a Better Buy in 2026?
Both companies are burning cash and trading at steep multiples, but their paths to profitability, and their risks, couldn't be more different.
Archived explainer. For the current picture see today's AEHR page.
AEHR TEST SYS (AEHR) is up +13.59% in the latest session. Our newswire has captured 1 story on AEHR across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
AEHR Test Systems surged 13.59% to $90.85 on Tuesday, rebounding from a morning low after a volatile intraday session. The stock opened with a 1.8% gap down but reversed sharply to close near its session high. The move appears to reflect a combination of retail interest and a broader market rotation into technology names, despite the company’s ongoing financial challenges.
The stock began the session at $78.54, significantly below the prior close of $79.98. It quickly fell to $73.78 before reversing course and climbing throughout the day. By 2:15 PM ET, AEHR reached a high of $91.29 before settling at $90.85. The session saw 1.3 million shares traded, which is 0.4 times the 3-month average daily volume. The stock’s sharp reversal suggests a potential short-covering rally or a shift in sentiment among retail traders. The Motley Fool recently published a comparative analysis of AEHR against C3.ai, highlighting the divergent paths of the two unprofitable technology firms. Meanwhile, Benzinga reported on a recent shelf prospectus filed by AEHR, though the offering size remains undisclosed.
AEHR remains unprofitable, with a trailing twelve-month (TTM) net margin of -14.3% and a revenue decline of 15.2% TTM. Its price-to-earnings ratio is negative, and its beta of 3.18 indicates extreme volatility. The stock has traded between $15.94 and $126.62 over the past 52 weeks. Recent insider activity has been bearish, with three separate sales totaling $2.6 million reported in the last 90 days. The 30-day average sentiment score has declined from 65 to 41 over the last week, suggesting a shift in market perception.
AEHR does not have an upcoming earnings date in the provided data. Investors should monitor coverage breadth and any developments related to the recently filed shelf prospectus for potential capital-raising activity.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Both companies are burning cash and trading at steep multiples, but their paths to profitability, and their risks, couldn't be more different.
More on AEHR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AEHR move explainers: 2026-10-30 · 2026-10-07 · 2026-09-25 · 2026-09-11 · 2026-09-10 · 2026-09-04 · 2026-09-03 · 2026-08-24 · 2026-08-21 · 2026-08-20 · 2026-08-19 · 2026-08-18 · 2026-08-17 · 2026-08-03 · 2026-07-28 · 2026-07-24 · 2026-07-22 · 2026-07-21 · 2026-07-20 · 2026-07-16